KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Raw Materials (2016 - 2018)

Teva Pharmaceutical Industries' Raw Materials history spans 9 years, with the latest figure at $1.3 billion for Q4 2018.

  • For the quarter ending Q4 2018, Raw Materials fell 8.67% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2018, down 8.67%, and an annual FY2018 reading of $1.3 billion, down 8.67% over the prior year.
  • Raw Materials for Q4 2018 was $1.3 billion at Teva Pharmaceutical Industries, down from $1.4 billion in the prior quarter.
  • The five-year high for Raw Materials was $1.5 billion in Q1 2018, with the low at $1.2 billion in Q4 2015.
  • Average Raw Materials over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2016.
  • Year-over-year, Raw Materials decreased 18.85% in 2014 and then increased 15.9% in 2016.
  • Tracing TEVA's Raw Materials over 5 years: stood at $1.3 billion in 2014, then dropped by 6.57% to $1.2 billion in 2015, then increased by 15.9% to $1.4 billion in 2016, then rose by 4.98% to $1.5 billion in 2017, then fell by 8.67% to $1.3 billion in 2018.
  • Per Business Quant, the three most recent readings for TEVA's Raw Materials are $1.3 billion (Q4 2018), $1.4 billion (Q3 2018), and $1.4 billion (Q2 2018).